Cancer startup GO Therapeutics signs $195m licensing deal with Roche
As per terms of the deal, Roche will secure worldwide and exclusive license from GO Therapeutics for cancer-specific targeting antibodies. The license will allow Roche to develop and
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.